Territory

Nathalie Maubon

nathalie.maubon@hcs-pharma.com I +33 3 20 79 11 30

Voir le site

Startup – Small Biotech

HCS PHARMA

Director

Researcher's interest in a few words:

Main field of activity

  • biologic model development;
  • biologic model application/user.

Target organs

  • brain;
  • liver.

Main collaborations

  • RHU Chopin (CHolesterol Personalized Innovation, 2016-2021);
  • LABCOM 2020-2025 (COMmmon LABoratory, public-private partnership) entitled Bio-PharMEMS, in conjunction with SMMiL-E;
  • ANR-funded consortium “MIMLIVERonChip” (2019-2022);
  • Eurostar project on clean meat (2020-2022), with BIOMIMESYS.

Keywords


Type/models systems

Organoids, spheroids & organ-on-a-chip;

Physio-pathological models

Cancer, neurodegenerative disease, metabolic disorders & cardiovascular disease;

Application areas

Organ development and physiopathology studies, diseases models, organ interaction studies, drug discovery, toxicity, drug safety, toxicology testing & personalized medecine.

Technologies

  1. structural material, tubing & materials (polymers, glass, hydrogel, ceramic…);
  2. cell biology, cell production, stem cells, iPSC & cell media;
  3. readout technologies, optical readers, fluoreaders, imaging & computational analysis.

Main research or activities topics

HCS Pharma is a biotechnological company offering services in pre-clinical in vitro research since 2014, with a specialization in high content analysis and high content screening (HCA/HCS) in 2D and 3D. HCS Pharma also sells products and services based on its proprietary 3D cell culture matrix – BIOMIMESYS® – and develops its own 3D cellular models using this hydroscaffold.
HCS pharma team has expertise in the development of new in vitro models and assays for pharmacological and toxicological studies in 2D and in 3D culture, which they propose to their customers from the pharmaceutical, nutraceutical and cosmetic industries. They report about the effect of tested molecules (drugs, ingredients, cosmetics) on cells using high throughput imaging (phase contrast, widefield and confocal microscopy) and subsequent image analysis.
BIOMIMESYS® technology is HCS Pharma’s proprietary 3D cell culture technology: this is a patented hydroscaffold based on hyaluronic acid, which is biofunctionalized with other extracellular matrix components. Its composition and rigidity are fully mastered to better mimic the cellular microenvironment of every tissue/organ. BIOMIMESYS® is compatible with OoC systems.

Contact


Adresse

Biocentre Fleming – Bâtiment A
250 rue Salvador Allende
59120 Loos France
France